For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Total revenue | - | 0* | - | |
| Research and development | 13,397,977 | 7,442,302* | 8,970,010 | |
| General and administrative | 6,599,759 | 3,474,154* | 3,708,959 | |
| Total operating expenses | 19,997,736 | 10,916,456* | 12,678,969 | |
| Loss from operations | -19,997,736 | -10,916,456* | -12,678,969 | |
| Changes in fair value of warrant liabilities | 482,474 | 110,883,441* | -61,598,908 | |
| Interest expense | 62,745 | 110,788* | 43,292 | |
| Interest income | 1,047,197 | -533,667* | 655,233 | |
| Other income | 626,873 | 836,141* | 765,881 | |
| Warrant issuance cost | - | - | 4,852,292 | |
| Warrant issuance expense | - | 1,213,073* | - | |
| Total other income | 1,128,851 | -111,904,828* | 58,124,438 | |
| Net gain | -18,868,885 | -122,821,284* | 45,445,469 | |
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | - | 46,366* | - | |
| Foreign currency translation gain (loss) | - | 34,114* | - | |
| Total comprehensive income (loss) | - | -122,740,804 | - | |
| Basic EPS | -0.35 | -4.389 | 0.5 | |
| Diluted EPS | -0.35 | -2.739 | -0.21 | |
| Basic Average Shares | 53,558,639 | 27,963,096 | 10,660,500 | |
| Diluted Average Shares | 53,558,639 | 44,817,123 | 77,863,263 | |
SAB Biotherapeutics, Inc. (SABSW)
SAB Biotherapeutics, Inc. (SABSW)